SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today reported financial results for the quarter ended June 30, 2017 and provided an update on its corporate activities and product pipeline.
Second Quarter 2017 and Subsequent Highlights
•Completed Enrollment in the U.S. Phase 3 AVERTS-1 Trial for OTIVIDEX™ in Ménière’s Disease, Results Expected in September 2017:
